OBJECTIVE: Prednisone (PRED) is recommended at discharge to reduce the relapse rate following emergency treatment for an asthmatic attack. However, PRED has systemic side effects. Inhaled anti-inflammatory medications, such as budesonide (BUD), are well tolerated. This study was designed to compare the effectiveness of PRED and BUD on relapse rate. DESIGN: A prospective, randomized, double-blind, double dummy, parallel group design.
T he management of acute asthma in the emergency department involves the use of bronchodilator therapy primarily with inhaled beta 2 -agonists (1) and, less often, ipratropium bromide (2), oxygen (1) and systemic glucocorticosteroids (GCSs) (3) . Historically, steroids were given intravenously (4) , but more recently, the use of oral GCSs has been recommended (5, 6) . Despite these recommendations, the management of acute asthma has been documented as suboptimal in the past (7) , and, although improvements were noted in a recent survey (8) , management still did not match published guidelines (9) . The reasons for suboptimal management of acute asthma are unclear because it has been shown that prednisone (PRED) given at the time of discharge reduces significantly the relapse rate to the emergency department (10) . In the past, a 10 to 14 day course of PRED was usually followed by a tapering dose of PRED. More recently, with inhaled GCSs, it was found that no tapering was required (11) .
The impact of multiple short courses of oral PRED is unknown, and some patients have documented significant psychological reactions to systemic steroids, which makes them reluctant to take PRED. Inhaled GCSs have been shown to have fewer systemic effects (12) . Asthma management might be improved if equivalence between PRED and budesonide Turbuhaler (Astra Pharma Inc, Mississauga) (BUD) could be demonstrated for follow-up of an acute exacerbation. The primary objective of this study was to compare the incidence of asthma relapse during one week of treatment with a high dose of PRED or inhaled BUD in patients who were deemed well enough to be discharged from the emergency department following a severe acute asthma attack. The second objectives of this study were to compare the effects of BUD and PRED on forced expiration volume in 1 s (FEV 1 ), peak expiratory flow (PEF), asthma symptoms and quality of life (QoL) results (13) .
PATIENTS AND METHODS

Patient characteristics:
Patients 15 to 70 years of age were recruited in the emergency department after having an acute asthma exacerbation (a progressive increase in dyspnea and a history of asthma as defined by the American Thoracic Society criteria) (14) . Patients had to be well enough to be discharged (postbronchodilator FEV1 greater than 50% of predicted normal) (9) . Postbronchodilator reversibility of greater than 15% was documented for FEV1 or greater than 20% for PEF compared with baseline, to establish the diagnosis of asthma and exclude patients who had chronic obstructive lung disease. Patients with chronic obstructive lung disease would not have reversible air flow obstruction and by showing reversible air flow obstruction, we confirm the diagnosis of asthma. All patients had to be able to use Turbuhaler correctly.
Exclusion criteria were as follows: intolerance to oral GCSs or inhaled GCSs; peptic ulcer disease; active tuberculosis; fungal infection; or insulin-dependent diabetes. Patients who had moderate to severe hypertension (diastolic blood pressure greater than 105 mmHg) and patients who were pregnant, lactating or of childbearing age and not using effective means of contraception, were excluded. Patients were also excluded if they had received a course of oral GCSs in the four weeks before visit 1 or if they required more than 1600 µg/day of inhaled GCS as maintenance therapy. Additionally, patients who had major comorbid illnesses that might interfere with the study outcomes were excluded.
One hundred and eighty-five patients who had acute asthma presented to the three university-affiliated, urban emergency departments. These patients fulfilled the inclusion and none of the exclusion criteria and were placed randomly in the study (175 patients were eligible for the intent-to-treat group). Study design: The randomized, controlled trial was a double-blind, double dummy, parallel group design. Patients were treated with bronchodilators and supplemental oxygen at the discretion of the emergency department staff. All patients were required to receive one dose of systemic GCSs, either methylprednisolone 125 mg intravenously or oral PRED 40 to 60 mg before randomization. Eligible patients were then randomly placed in groups for treatment with inhaled BUD 2400 µg/day (the approved maximum dose in Canada) given in divided doses qid or PRED 40 mg once daily in the morning. Patients were also stratified into two groups based on their regular inhaled GCS requirement during the month before presentation to the emergency department (less than or equal to 400 µg for stratum one and greater than 400 µg for stratum two).
Treatment continued for seven to 10 days after emergency department discharge. After four days, telephone contact to assess asthma control was attempted for each patient. All patients were scheduled for a return visit seven to 10 days after emergency department discharge. In the event of a deterioration in lung function, the patient was asked to return to the emergency department earlier. Patients who failed to return for the final visit were contacted by telephone, and encouraged to come in for a visit and return the study medication. If the patient could not return for a visit, the study staff attempted to obtain, over the telephone, current peak flow measurements, symptom scores and information about any possible asthma relapses. Patients were also given instructions on how to taper their study medications. Study drugs: BUD Turbuhaler and its placebo were manufactured by Astra Pharmaceutical Production AB (Sodertalje, Sweden). PRED and its placebo were supplied by the Pharmacia Upjohn Company (Toronto). The active and placebo treatments (Turbuhaler devices and PRED tablets) were identical in appearance. As a measure of compliance, the remaining doses in each Turbuhaler were counted and an estimate of the number of doses taken was calculated. The number of pills returned was used in calculation of compliance. Treatment plan: Patients fulfilling the inclusion and with none of the exclusion criteria, were discharged with BUD 2400 µg/day (three inhalations of 200 µg, qid) or placebo with a suggested schedule and PRED or placebo 40 mg/day. Following discharge from the emergency department, patients were requested to continue on prestudy doses of theophylline and ipratropium, but not to take their prestudy inhaled GCSs. Patients were also instructed to use only their short-acting beta2-agonist for symptomatic relief. The study drug was continued for at least seven to 10 days depending on the day patients returned. Ethical conduct and review: Hospital and University approval for this study was received from the centres' Ethics Review Boards before the study started. Patients gave their informed consent before enrolment in the study. The study was performed in accordance with the principles stated in the 'Guidelines on Research Involving Human Subjects' issued by the Medical Research Council of Canada, which encompasses the Declaration of Helsinki. Clinical assessments: Demographic data, concomitant medications and disease, and medical history were documented at baseline after treatment in the ED. At baseline and at visit 2, before and 30 mins after, postbronchodilator spirometry was performed. The highest of three measurements for FEV 1 , PEF and when possible, for forced vital capacity was documented to assess lung function.
When the patient was at home, asthma severity was selfassessed each evening for the previous 24 h as follows: 0 equals no symptoms; 1 equals mild symptoms present but not troublesome; 2 equals moderate symptoms present but not sufficient to interfere with daily activities; or 3 equals severe symptoms sufficiently troublesome to interfere with normal activity. PEF was also measured and recorded at home in the morning and evening using a mini-Wright (Clement Clark International Ltd, Essex, United Kingdom) peak flow meter before patients took their study medications. Study drugs and other medications were recorded in the diary card and on the case report form. In the event of a sore throat or thrush, swabs for candida were completed when deemed necessary by the physician, but there were no reports of candida during this study. The self administered Asthma Quality of Life Questionnaire (AQLQ) (13) was completed by the patient at baseline and at visit 2. During the study period, adverse events were documented by spontaneous reporting of symptoms and after visit 2 by asking if any health problems had been experienced since the last emergency department visit. Statistical determination of sample size: The main objective of this study was to determine if the two treatments were clinically equivalent. A difference in relapse rate of greater than 10% was considered a priori to be clinically significant (15) . If both treatments had a relapse rate of 5%, 75 evaluable patients were required in each group (150 in total). This calculation was based on a two-sided c 2 test without continuity correction at alpha=0.05 with power (1-B)=80%. The null hypothesis stated that the absolute treatment difference was greater than or equal to 10%, while the alternate hypothesis assumed that the absolute treatment difference was less than 10%. In relation to conventional hypothesis testing, the meaning of alpha and beta is reversed (ie, alpha is the risk of falsely rejecting the hypothesis of nonequivalence and [1-B] was the probability of accepting the hypothesis of equivalence, when it was true).
Statistical methods and analysis plans:
The principal outcome measure was the relapse rate, defined as a return to the ED. Secondary efficacy variables were measurements of FEV 1 (in the daily diary and in the clinic) during the study period. The changes from baseline to the end of treatment for FEV 1 (before and after bronchodilator) and PEF were compared between the two treatment groups. Secondary variables were the changes in symptom scores and AQLQ. Parametric and nonparametric tests were used for the comparisons where applicable. Two-tailed tests of significance were used. P<0.05 was considered statistically significant. Analysis was performed using a modification of the intent-to-treat approach that is termed all patients treated. In this approach, all patients who have been randomized to treatment and who received at least one dose of study drug were considered for inclusion in the analysis except for patients who discontinued treatment an early stage because of baseline characteristics, or who had no measurements of efficacy made during the treatment period. In addition, patients with only visit 1 and no diary card data were excluded from the analysis. These criteria were decided a priori and included in the initial study protocol. All decisions regarding the statistical analysis were made before breaking the study code, and all results were expressed with a 95% CI of treatment difference.
Logistical regression was used to test for a centre effect and the significance of FEV 1 at baseline for the primary variable (relapse rate). The results of the regression showed no significant effect for either of these variables, so they were excluded from subsequent analysis. Analysis of covariance (ANCOVA) with the three factors (ie, treatment, centre and treatment-by-centre interaction) was used for FEV 1 , PEF, symptoms scores and AQLQ scores. As well, the baseline value was incorporated in the model as a covariate for postbronchodilator FEV 1 as a percentage of predicted normal, PEF, symptom scores and AQLQ results, respectively.
The changes in FEV 1 from baseline to visit 2 were analyzed by ANCOVA. The area under the curve was calculated per patient from day 1 to day 10 for diary variables (PEF in the morning, PEF in the evening and symptom scores). Data analysis was performed using SAS version V6.08 under VMS\VAX V6.1 (SAS Institute, Cary, North Carolina).
RESULTS
One hundred and eighty-five patients were enrolled and placed randomly into the study groups. Eight patients (five PRED and three BUD) were soon lost to follow-up. Two further patients were excluded, both from the PRED group; one patient did not have asthma and the second received both active treatments. Thus, 10 patients were excluded from the analysis. The two treatment groups were comparable at base- Thirty-four patients withdrew from the study for various reasons. Table 2 summarizes the main reasons for withdrawal, which were adverse events and patients lost to follow-up (ie, the patient was unreachable after discharge so no relapse information could be obtained). The most common adverse events were dyspepsia (n=2 PRED, n=7 BUD), nausea (n=4 PRED, n=6 BUD) and headache (n=6 PRED, n=4 BUD), and were only of mild and moderate intensity. Twelve patients withdrew from the study because of an adverse event; six patients who received at least one dose of BUD withdrew because of an asthma exacerbation. Of the five patients who received PRED, one withdrew because of a 'funny-taste in their mouth, increased appetite, nausea and shakiness' and four withdrew because of an asthma exacerbation (these relapses were included in the total count with the patients who relapsed but did not discontinue from the study).
The relapse rate was comparable between the PRED and BUD treatment groups (10 relapses and nine relapses, respectively). The 95% CI of treatment difference (ie, -7.5% to 11%) showed that BUD was at least as effective as PRED. The improvements with treatment for both FEV 1 and PEF (Table 3) were not significantly different between BUD and PRED treatment groups. As expected, there was a significant improvement over time for both groups for prebronchodilator FEV 1 (49% to 82% PRED and 47% to 83% BUD) and for PEF.
Asthma symptoms and AQLQ results (Table 4) showed a similar pattern with comparable improvements for the BUD and PRED treatment groups and the expected significant improvement over time with both treatments.
DISCUSSION
This study has shown that patients can be discharged safely from the emergency department on high dose inhaled BUD instead of oral PRED. The two treatments were shown to be equivalent. There were no significant differences in the side effects profile between the groups. The doses of oral GCSs and inhaled GCSs in this study were chosen based on the findings of Toogood et al (12) who showed that 2000 µg of BUD, by inhalation, resulted in an equivalent antiinflammatory effect as 40 mg of oral PRED. Because there was approval for 2400 µg BUD in Canada, we chose to use this higher dose. We also used a four-times daily regimen because an earlier study by Malo et al (16) demonstrated that a qid dosing schedule in ambulatory people with asthma gave better control than a twice-daily regimen. However, it appears that a lower dose of BUD is just as effective (17) . A study performed in Thailand (17) showed similar results to ours for spirometry. In that study, 81 patients were randomly selected to receive 1600 µg of BUD or 40 mg of PRED tapered daily over seven days. Despite the early PRED taper, there were no differences for FEV 1 , PEF or rescue medication use between the groups. It could be argued that the comparison made in this study (17) was not representative of current practice in which is PRED is given for seven to 14 days before tapering begins (9) . Thus, patients in the PRED arm were undertreated.
To the authors' knowledge, this is the first North American study to address the issue of substitution of oral GCSs with high dose inhaled GCSs for the follow-up treatment of patients with asthma severe enough to require management of an acute exacerbation in the emergency department. A larger, family physician, office-based study in the United Kingdom compared high dose fluticasone propionate (n=206) with oral prednisolone (n=207) in patients who had less severe airflow obstruction (18) . Patients were randomized to receive either 2000 µg/day of fluticasone propionate or a tapering dose of prednisolone 40 mg. The setting for the study ensured that the patients were less sick (ie, PEF of 75.1% of predicted normal) than the patients in the current study, who presented with a prebronchodilator FEV 1 of 45% of predicted normal. In an accompanying editorial, Griffiths (19) , although welcoming the British study, indicated the need for sicker patients to be studied. We have achieved this objective in the current study. In addition, there have been a number of smaller studies published that have addressed the issue of adjunct inhaled corticosteroid in acute asthma (20) (21) (22) . It has been suggested that QoL is an important outcome and should be assessed in clinical trials of asthma interventions (13) . The AQLQ has been shown to be a reliable, valid and responsive instrument for use in the follow-up of patients discharged after an acute asthma exacerbation (20) . In our study, QoL provided important feedback about the patients' health, as shown by the improvement in well being. Clinical improvement by objective measures occurred in parallel to that for QoL. This is in agreement with a preliminary study in which we showed a clear difference in asthma QoL between patients hospitalized for acute asthma compared with community controls (21) .
There were no major differences in the adverse event profiles in the treatment groups. Despite this, there have been reports of idiosyncratic reactions to short courses of oral GCSs (22) , especially in sicker patients when combined with neuromuscular relaxing agents and when the corticosteroids were given intravenously (23), myopathy has been reported. A potential argument against using high dose inhaled GCSs compared with oral PRED is cost. Based on current recommendations, most asthma patients who are likely to have an exacerbation should already be taking inhaled GCSs because its use has been shown to reduce their risk of death (24) . A logical extension of our study would be confirmation that an increase in inhaled GCSs in the early stages of an exacerbation would prevent the exacerbation from progressing to the extent that a visit to the emergency department is required. Given the documented high costs of asthma care delivered by emergency departments and hospitalizations (25, 26) , the use of high dose inhaled GCSs in the manner described in this study at an earlier stage may be more cost effective in the long term. Such a result will only be achieved if asthma patients are educated to manage their disease proactively (to be able to change therapy, ie, increase anti-inflammatory therapy early in an asthma exacerbation) (27) and to use their predetermined action plan early (28) .
Recently, a study has been published that extends our results; Rowe and colleagues (29) randomized patients to oral PRED versus PRED and 1600 µg of BUD after discharge from the emergency department. In the combination arm of the study, the relapse rate was 12.8% compared with 24.5% in the placebo (PRED alone) arm of the study. These intriguing results need to be treated cautiously because the rate of relapse in the PRED alone group is close to that of placebo groups in previously published studies. The longer and more comprehensive follow-up in the recent study may account for these differences. These new data, as well as the recent study by Rodrigo and Rodrigo (30) , suggest that inhaled GCSs may have an important complimentary role to systemic PRED in the management of acute asthma. The Uruguay study (30) showed that the addition of flunisolide 1 mg every 10 mins in the first 3 h of an acute asthma attack, along with inhaled salbutamol, gave a significantly better bronchodilator response (P=0.041) than salbutamol alone.
Our study has a number of limitations, most notably, a relatively high loss to follow-up and small sample size. In terms of loss to follow-up, seven of the 10 patients with no follow-up were in the PRED group, thus, if anything, their inclusion would be likely to skew the results in favour of PRED. In addition, in showing equivalence of relapse rate, the CI crossed 10%, which was the a priori level set as significant. However, the 95% CI was calculated based on PRED minus BUD. Thus, the upper limit of the CI actually exceeded the a priori clinically relevant relapse rate of 10%. We therefore feel justified in saying that we have shown at least equivalence. Despite these limitations, we feel our results in conjunction with other, more recent smaller studies (31,32,) suggest that high dose inhaled corticosteroids have a role to play in acute asthma. Further studies need to address the optimal dose and duration of inhaled therapy as well as the benefits of combination therapy. The cost effectiveness of such regimens also need to be determined.
